INTRODUCTION
The accumulation of B-cell acute lymphoblastic leukemia (B-ALL) blasts results from the disruption of developmental checkpoints that normally regulate the generation of functional mature B cells. 1, 2 One of these checkpoints, as pro-B lymphocytes (cytoplasmic Igμ − /surface IgM − ) transition to become pre-B lymphocytes (cytoplasmic Igμ + /surface IgM − ), involves surface expression of the precursor-B-cell receptor (pre-BCR). 3 Expression of a functional pre-BCR supports the survival of pre-B cells, induces their rapid proliferative expansion, and ensures their differentiation into more mature B cells. 4 B-cell progenitors that fail to assemble a functional pre-BCR lack pre-BCR-dependent survival signals and are removed from the pool of developing B cells. 5, 6 The structure of the pre-BCR closely resembles that of the BCR on mature B cells. 7 Both contain two immunoglobulin μ (Igμ) heavy chains and the signal-transducing heterodimer of Igα (CD79a) and Igβ (CD79b). However, instead of the immunoglobulin light chain (LC), the Igμ of the pre-BCR pairs with the surrogate LC, a heterodimer consisting of the invariant proteins λ5 (CD179b) and VpreB (CD179a). The surrogate LC is not only required for proper assembly and surface expression of the pre-BCR but also for the distinctive mechanism by which it is activated, referred to as 'cell-autonomous signaling'. Highly conserved regions within the Igμ C H 1 domain and λ5 facilitate the aggregation of multiple pre-BCR complexes, followed by the engagement of LYN and spleen tyrosine kinase (SYK) and subsequent activation of downstream signaling cascades including PI3K/AKT, ERK and BTK/PLCγ2. [8] [9] [10] [11] Pre-BCR aggregation also induces its rapid internalization; consequently, active pre-BCR signaling is associated with low pre-BCR surface expression.
Besides its importance for normal B-cell development, several studies suggest a role for the pre-BCR and its downstream signaling components in B-ALL. [12] [13] [14] [15] [16] [17] In Ph + -ALL, the oncogenic fusion kinase BCR-ABL activates pre-BCR downstream effectors, such as BTK, BACH2 and BCL6. 15, 18, 19 TCF3-PBX1 + B-ALL cells depend on Igα and Igβ expression and are sensitive to the combined BTK-, SRC-and ABL kinase inhibitor dasatinib. 20 Similarly, small-molecular inhibitors of SYK were shown to induce apoptosis and reduce tumor cell burden in several xenograft models of B-ALL 21, 22 and recently Geng et al. 14 identified a subgroup of B-ALL, characterized by the presence of tonic pre-BCR signaling and the sensitivity to small-molecular inhibitors of SYK and BTK. Whether inhibition of pre-BCR signaling using, for example, SYK inhibitors is more broadly applicable across B-ALL subsets, as suggested in earlier studies [21] [22] [23] , or restricted to pre-BCR + subsets of patients based on more recent studies, remains controversial, given these discrepant data. 14, 20, 24 This has major impact on the conceptualization of future clinical trials, which could be restricted to pre-BCR + patient subsets or not. Prior studies of pre-BCR signaling in normal and malignant B cells relied on the use of tyrosine kinase inhibitors or mouse models of B-cell development, two approaches that have some drawbacks. Tyrosine kinase inhibitors harbor off-target effects, and pre-BCR checkpoints in humans and mice differ significantly, which both can introduce variables and complicate data interpretation. 25, 26 Our comparative approach of gene deletion and pharmacological inhibition of pre-BCR signaling avoids some of these limitations, and therefore sheds new light onto these issues.
MATERIALS AND METHODS

Cell lines, xenografts and patient samples
Please see Supplementary Methods.
Flow Cytometry
The following antibodies were used throughout the study: PE anti-human pre-BCR; PE anti-human λ5; PE anti-human VpreB (BioLegend, San Diego, CA, USA); R-PE anti-human IgM; APC anti-human IgM (SouthernBiotech, Birmingham, AL, USA); APC anti-human SYK (eBioscience, San Diego, CA, USA); PE anti-human CD19 (BD Pharmingen, San Diego, CA, USA); and PE anti-human AKT (pS473) (BD Phosflow; BD Bioscience, San Jose, CA, USA). To detect cell surface antigens 5 × 10 5 cells were stained with the respective antibodies diluted in 100 μl FACS-Buffer (0.5% bovine serum albumin w/v in RPMI1640) for 30 min at 4°C protected from light. To measure intracellular antigens cells were fixed, permeabilized and stained using the BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Bioscience). For each antibody respective Isotype antibodies were used as controls. After staining, cells were washed once and mean fluorescence was assessed on a FACSCalibur (BD Bioscience).
Proliferation and viability
For in vitro efficacy studies of PRT318 and LY294002 2 × 10 4 cells were seeded in 100 μl in 96-well plates in cell culture medium without phenol red and treated with PRT318 or LY294002 for 72 h, followed by XTT assays (XTT Cell Proliferation Assay, Trevigen, Gaithersburg, MD, USA).
To assess cell proliferation after Igμ-KO, MYC-KO and FOXO1-AAA expression, 2 × 10 4 cells were seeded in 100 μl in 96-well plates. At the indicated time points cells were transferred into FACS tubes followed by the addition of 300 μl viability staining solution (see below) containing 10 μl CountBright counting beads (Life Technologies, Carlsbad, CA, USA). Cells were analyzed via flow cytometry and absolute numbers of viable cells per well were calculated based on the ratio of acquired beads and total numbers of beads/tube.
To assess cell viability cells were stained with 2 μg/ml propidium iodide and DiOC 6 (60 nmol/l) as described previously. 27 CRISPR/Cas9 and FOXO1-AAA expression Guide RNA (gRNA) design and cloning was performed according to the protocol by Ran et al. 28 For a more detailed description of the procedure please refer to the Supplementary information. For guide RNA sequences please refer to Supplementary Table 4. 1099 pcDNA GFP FKHR AAA (FOXO1-AAA) was a gift from William Sellers (Addgene plasmid # 9023). 29 Cells were transfected as described above. GFP + cells were sorted 24 h after electroporation and subjected to functional and molecular testing.
Confocal microscopy
The following dyes and antibodies were used for confocal microscopy: CellTracker Green CMFDA (Molecular Probes, Life Technologies), antihuman FOXO1 primary antibody (Cell Signaling Technologies, Danvers, MA, USA), Alexa Fluor 647-conjugated species-specific secondary antibody (Molecular Probes, Life Technologies). For a detailed description of the staining protocol refer to Supplementary Information.
Gene expression profiling and gene set enrichment analysis (GSEA)
Total RNA was extracted with the RNAqueous kit (Ambion, Austin, TX, USA). After confirmation of RNA quality (RIN46.6, median 7.2) using a Bioanalyzer 2100 instrument (Agilent, Santa Clara, CA, USA), 300 ng of total RNA was amplified and biotin-labeled through an Eberwine procedure using an Illumina TotalPrep RNA Amplification kit (Ambion) and hybridized to Illumina HT12 version 4 human whole-genome arrays. Data processing was done as previously described. 30 The B-cell progenitor GEP data set (GSE45460) 31 and St. Jude B-ALL data set (GSE33315) 32 were obtained from the NCBI GEO gene expression database and processed using the Gene Pattern Server provided by the Broad Institute (Cambridge, MA, USA). Gene set enrichment analysis (GSEA) was performed using the GSEA software provided by the Broad Institute. 33, 34 Hierarchical clustering with the Average linkage clustering method was performed with Cluster 3.0 (University of Tokyo, Human Genome Center).
Heatmaps and dendrograms were visualized with Java TreeView (v1.1.6r4).
Statistical analysis
Statistical analyses were performed with GraphPad Prism v6 (La Jolla, CA, USA). Figure 1A and Supplementary Table 1 ). We applied these signatures to microarray data of 483 primary B-ALL samples, with various cytogenetic abnormalities, from the St. Jude Children's Hospital. 32 Unsupervised hierarchical clustering of the arrays revealed one group of B-ALL samples with GEP expression similar to normal pre-B cells (Figure 1a ), hereafter referred to as pre-B ALL. This cluster comprised 79 (16.4%) cases; half of these (49.4%) harbored t(1;19), followed by cases with nonrecurrent cytogenetic abnormalities (27.8%), mixed-lineage leukemia rearrangements (16.5%) and hypodiploidy (6.3%) ( Table 2 ). Western Blot analysis revealed the presence of key constituents of the pre-BCR signaling cascade in all pre-B-derived ALL cells tested (Supplementary Figure 1D) .
Western blotting
To assess the role of pre-BCR signaling in pre-BCR + ALL, we subsequently studied the effects of pre-BCR knockout (KO) on proliferation and survival of the pre-BCR + ALL cells RCH-ACV and SMS-SB. Targeting Figure 1g ). Although SYK is ubiquitously expressed in B-ALL, the pre-BCR − cells REH (t12;21) and Nalm-21 (t9;22), both were highly resistant to SYK KO, suggesting that SYK is predominantly involved in the maintenance of pre-BCR + ALL.
SYK serves as a therapeutic target in pre-BCR + ALL
To delineate the role of SYK as a therapeutic target for B-ALL, we treated pre-BCR + and pre-BCR − B-ALL cells with the highly specific SYK inhibitor PRT318 (Figure 2a and Supplementary Figure 2A) . 38, 39 In line with our previous results, pre-BCR + cells were particularly sensitive to SYK inhibition and IC 50 values of PRT318 in these cells corresponded closely to IC 50 values of PRT318 in SYK-dependent diffuse large B-cell lymphoma (DLBCL) cells (Supplementary Figure 2B) . 39, 40 Similarly, pre-BCR + ALL cells were also more sensitive to R406 (Fostamatinib), an alternative ATP-competitive inhibitor of SYK ( Supplementary  Figures 2C and D) .
To further investigate the efficacy of pharmacological SYK inhibition, we studied the effects of PRT318 in a xenograft mouse model of B-ALL. We inoculated NOD/SCID mice with pre-BCR + (X018) or pre-BCR − (X089) B-ALL cells, and following engraftment (45% huCD19 + cells in peripheral blood) initiated therapy with PRT318 (30 mg/kg BID) or vehicle control (5% Captisol). After 10 days mice were sacrificed and subjected to the assessment of Figure 2E) . Similarly, we noted that primary B-ALL cells that were isolated directly from patient samples and that had a pre-B immunophenotype (cyto-Igμ + and surface IgM − ) were more sensitive to SYK inhibition with PRT318 than B-ALL cells with a pro-B immunophenotype (cyto-Igμ − , surface IgM − ; Figure 2c and Supplementary Table 3) . We furthermore tested the activity of the SYK-selective inhibitor PRT062607 (ref. 41) in an alternative model of pre-BCR + ALL, using pre-BCR + xenograft-expanded ICN12 cells (Supplementary Figure 2F) . We found that PRT062607 significantly prolonged survival of mice inoculated with ICN12 cells (Figure 2d) , further corroborating the activity of SYK inhibition in this disease subset.
Constitutive pre-BCR signaling selectively modulates PI3K pathway activity Studies of the pre-BCR in normal B-cell development demonstrated that activation of the BTK/BLNK/PLCγ2, PI3K/AKT and ERK pathways are essential for transmitting pre-BCR-derived downstream signals. 10, 11, 42 To understand the molecular mechanisms underlying the dependence of pre-BCR + ALL on the pre-BCR and SYK, we examined the activity of these signaling molecules after (e) Igμ-KO and control cells were flow sorted followed by the assessment of the indicated proteins by western blot analysis. To assess phosphorylation changes in response to PRT318, SMS-SB cells were pretreated with the indicated concentrations of PRT318 for 2 h. Immunoblots are representative for two independent experiments. (f) Pre-BCR − (REH, RS4;11, Tanoue, BALL-1) and pre-BCR + (RCH-ACV, SMS-SB, Nalm-6) cells were treated with 0.5 μM PRT318 for 2 h, followed by the assessment of pAKT and its densitometric quantification in ImageJ. Bar graphs depict the average reduction of pAKT relative to control (± s.d.). ****P o0.0001 MannWhitney test. (g) Effects of PRT318 on pAKT levels in pre-BCR + and pre-BCR − xenograft cells. Cells were incubated with 1 μM PRT318 for 2 h before assessing AKT phosphorylation via flow cytometry. **P o0.001 Mann-Whitney test. (h) Cells were treated for 72 h with the indicated concentrations of LY294002 before assessing its effects via XTT proliferation assays. Results depict means ± s.d. of three independent experiments. ANOVA, analysis of variance.
Igμ-KO or treatment with PRT318. Both approaches consistently demonstrated a marked reduction in AKT phosphorylation, but only minor reductions in ERK and BTK phosphorylation (Figure 2e and Supplementary Figure 2G ), pointing toward a central role of PI3K in pre-BCR-signaling in B-ALL. To determine whether the effects of SYK inhibition on PI3K signaling were specific for pre-BCR + ALL, we treated pre-BCR − and pre-BCR + B-ALL cells with increasing concentrations of PRT318 and assessed changes in AKT phosphorylation (Figure 2f and Supplementary Figure 2H ). In accordance with our results from the functional assays, pre-BCR + ALL exhibited an almost complete loss of AKT phosphorylation in response to PRT318, but there was only minor pAKT modulation by PRT318 in the other groups of B-ALL. We similarly found higher pAKT levels in pre-BCR + xenograft cells (Supplementary Figure 2I) , which were reduced selectively by PRT318 (Figure 2g ), indicating that constitutive activation of AKT by the pre-BCR and SYK characteristically occur in pre-BCR + ALL. The importance of PI3K was further supported by the finding that PRT318-sensitive cells were significantly more sensitive to the pan-PI3K inhibitor LY294002 than were PRT318-resistant cells (Figure 2h ).
Inhibition of pre-BCR signaling activates FOXO1 transcriptional activity Effects on FOXO transcription factors are important downstream consequences of PI3K/AKT signaling in various tissues. During B-cell development, inactivation of FOXO transcription factors through AKT-mediated phosphorylation has been shown to be essential for delaying immunoglobulin gene rearrangement and facilitating the expansion of pre-BCR + B-cell progenitors. 11 Moreover, inactivation of FOXO family members was shown to be involved in the development of a variety of malignancies, including leukemia. [43] [44] [45] To determine whether inactivation of FOXO transcription factors is also involved in the maintenance of pre-BCR + ALL, we first analyzed expression levels of FOXO family Figure 3A) . FOXO1 predominates in B-lineage-restricted progenitor cells (Fractions A to E), and its expression levels inversely correlate with the degree of cell proliferation at each developmental stage (Fraction A/C: high proliferation, low FOXO1; Fraction BC/D/E: no proliferation, high FOXO1). In accordance with these data, our immunoblot analyses of pre-BCR + ALL cells demonstrated expression of FOXO1 and its phosphorylation at residues responsible for nuclear export and cytoplasmic degradation (Supplementary Figure 3B) . Treatment with increasing concentrations of PRT318, or Igμ-KO, resulted in reduced FOXO1 phosphorylation and increased total protein levels of FOXO1 selectively in pre-BCR + ALL cells (Figures 3a and b and Supplementary Figure 3C ). This was accompanied by the translocation of FOXO1 from the cytoplasm to the nucleus (Figure 3c) , suggesting an increase in FOXO1 transcriptional activity in response to the inhibition of pre-BCR signaling. Accordingly, we also observed increased protein levels of established FOXO1 transcriptional targets, such as BLNK and p27 after treatment with PRT318 or Igμ-KO (Figures 3d and e) . We subsequently transfected RCH-ACV cells with a constitutively active form of FOXO1 (FOXO1-AAA). Similar to the effects of Igμ-KO and PRT318, FOXO1-AAA-expressing cells proliferated less than control cells and displayed upregulation of p27 and BLNK (Figures 3f and g ). To evaluate the role of FOXO1 inactivation in B-ALL patient samples, we compared gene expression profiles of RCH-ACV cells expressing either FOXO1-AAA or the respective empty vector control. Using a minimum absolute fold-change threshold of ⩾ 2, we identified genes that were induced in response to FOXO1-AAA (Supplementary Table 5 ). GSEA revealed that this set of genes was significantly enriched, in the expected direction, in the spectrum of genes differentially expressed between the pre-B ALL and non-pre-B ALL samples of the St. Jude GEP data set (Figures 3h and i and Supplementary Table 6 ). This confirms that constitutive pre-BCR signaling and FOXO1 inactivation contribute significantly to the distinct phenotype of pre-B ALL.
The pre-BCR regulates MYC in a FOXO1-dependent manner To identify additional targets of the pre-BCR in B-ALL we determined global gene expression changes in RCH-ACV and SMS-SB in response to Igμ-KO (Supplementary Table 7 ). Using GSEA we probed the list of genes regulated by the pre-BCR for the enrichment of gene sets provided by the Molecular Signatures Database (MSigDB v4.0). Among the most significantly enriched (false discovery rate o 0.001) were gene sets associated with the suppression of the transcriptional activity of MYC (Figure 4a ). In view of its importance for cell proliferation, survival and metabolism and its frequent deregulation in other B-cell malignancies, the potential involvement of MYC in pre-BCR + ALL was of particularly interest to us. In agreement with the GSEA, Igμ-KO significantly suppressed MYC mRNA and protein expression levels in RCH-ACV and SMS-SB (Figures 4b and c) . Similarly, PRT318 and LY294002 significantly reduced MYC protein levels, indicating that the pre-BCR regulates MYC in a SYK-and PI3K-dependent manner (Figure 4d) . Further emphasizing the importance of MYC in transducing signals from the pre-BCR, RCH-ACV and SMS-SB cells were highly sensitive to KO of MYC (Figure 4e and Supplementary Figure 4A) .
Finally, we addressed whether FOXO1 could also be involved in the suppression of MYC in pre-BCR + ALL. This hypothesis was in part suggested by the nature of differentially expressed genes in RCH-ACV cells in response to FOXO1-AAA expression, which, according to GSEA, also bore evidence of reduced MYC activity (Supplementary Figure 4B) . Furthermore, Gan et al. 47 reported that FOXOs are capable of modulating MYC mRNA expression through the induction of Mxi-1 and mir-145. Expression of FOXO1-AAA in RCH-ACV cells caused a substantial reduction of MYC protein levels (Figure 4f ), indicating that pre-BCR signaling indeed modulates MYC expression in a FOXO1-dependent manner.
DISCUSSION
In mature B-cell malignancies, the use of microarray-based GEP has contributed significantly in a better understanding of disease biology. In DLBCL, the comparison of GEPs from normal and malignant B cells resulted in the identification of two DLBCL subtypes, activated B cell-like and germinal center B cell-like DLBCL, characterized by a distinct cell of origin and differing survival mechanisms. 48 Using a similar approach we identified a subgroup of B-ALL with a gene expression profile reminiscent of normal pre-BCR + pre-B cells (pre-B ALL). Pre-B ALL cells were highly sensitive to the KO of Igμ and SYK, thereby suggesting that pre-BCR + ALL cells remain dependent on constitutive pre-BCR signaling despite their malignant transformation. The presence of TCF3-PBX1 + , mixed-lineage leukemia-rearranged and hypodiploid patient samples in the cluster of pre-B ALL samples and the complete absence of ETV6-RUNX1 + and BCR-ABL + cases indicates that the pre-B phenotype is associated with certain groups of cytogenetic abnormalities. However, whereas almost all TCF3-PBX1 + cases (98%) belong to the group of pre-B ALL only a fraction of mixed-lineage leukemia-rearranged (45%) and hypodiploid (26%) cases exhibit the pre-B phenotype, suggesting that additional factors shape disease biology in the latter two subtypes. Based on frequency, sample composition and the underlying molecular characteristics the group of pre-B ALL closely resembles the group of B-ALL with tonic pre-BCR signaling, identified by Geng et al.
14 through RPPA. Indeed, in our analysis we also observe increased expression of the pre-BCR pathway components Igμ, λ5, VpreB and SYK in pre-B ALL samples.
The KO of Igμ revealed that proliferation of pre-B ALL cells requires constitutive signals from the pre-BCR. This signaling activates PI3K in a SYK-dependent manner, which results in the inactivation of the tumor suppressor FOXO1 and deregulation of MYC. Importantly, a small-molecule inhibitor of SYK potentially suitable for clinical use (PRT318) abrogated constitutive pre-BCR signaling and its downstream effects in vitro and exhibited promising effects in two in vivo models of pre-BCR + ALL, thereby providing a rationale for testing the clinical activity of SYK inhibitors in pre-BCR + B-ALL. In this respect, our data challenge two recent reports in which SYK kinase inhibitors were tested in a variety of B-ALL patient samples and xenograft models of B-ALL, whose authors concluded that SYK is a valuable therapeutic target in all types of B-ALL, irrespective of immunophenotype, cytogenetic abnormalities (including Ph + cases) and pre-BCR status. 21, 22 In contrast, our data suggest that SYK is only essential in the subgroup of pre-BCR + B-ALL cases. We did not observe responses to SYK-KO or PRT318 in pre-BCR − cells in vitro or in vivo. This correlated with a selective effect of SYK inhibition on AKT phosphorylation in pre-BCR + cases. These discrepancies might be related to off-target effects of the compounds tested in these previous studies. R406, for instance, inhibits a spectrum of other tyrosine kinases, besides SYK 49, 50 , including pathways that support B-ALL cell growth and survival (JAK2, PDGFRB and FLT3). 1, 51, 52 Our findings corroborate those of Wossning and co-workers 53 , who demonstrated that the transforming capacity of SYK in B-ALL depends on concurrent expression of the pre-BCR and MYC. In regards to Ph + -ALL, several publications indicate that the BCR-ABL fusion kinase is directly involved in the suppression of the pre-BCR and pre-BCR downstream targets, such as SYK and Igβ, in order to maintain its malignant phenotype. 18, 13, 16 Consistently, all BCR-ABL + B-ALL cells tested by us were pre-BCR − and highly resistant to SYK-KO or SYK inhibition.
We also studied the role of BTK in the pre-BCR signaling cascade. Despite recent reports on the efficacy of the BTK inhibitor ibrutinib in pre-BCR + ALL, both Igμ-KO and PRT318 did not interfere with BTK signaling activity, suggesting that BTK is dispensable for the pro-proliferating effect of the pre-BCR in B-ALL.
24,14 Accordingly, the reported effective concentrations of ibrutinib in pre-BCR + ALL are considerably higher than in established BTK-dependent B-cell malignancies, indicating that ibrutinib might exert its effects in pre-BCR + ALL through the inhibition of alternative targets. 24, 54, 55 A translational challenge arising from our data is how best to identify patients with pre-BCR-dependent B-ALL, likely to be sensitive to SYK inhibition, in the clinical setting. Since B-ALL cells must be arrested at the pre-B cell stage (cytoplasmic Igμ + , surface IgM − ) in order to express a functional pre-BCR, this immunophenotype should be a minimum requirement, and is already assessed routinely in clinical laboratories. By selecting primary patient samples based on these immune phenotype criteria we distinguished PRT318-sensitive pre-B-ALL cases from PRT318-resistant pro-B-ALL cases. We also implicated the potential of a gene expression signature to identify suitable cases, but this would also require a method suitable for the clinical laboratory and further validation.
Previous reports suggested that pre-BCR signaling is primarily involved in the maintenance of B-ALL harboring t(1;19), characterized by the expression of the E2A-PBX1 fusion protein 14, 20, 24 ; indeed, 98% of E2A-PBX1 + cases exhibit the pre-B ALL GEP phenotype, and this group is therefore enriched for pre-BCR + B-ALL cases. 56 However, within the cluster of pre-B ALL cases identified in the St. Jude GEP data, only 50% harbor the E2A-PBX1 fusion protein. Therefore, the t(1;19) does not appear to be a reliable indicator of pre-BCR-dependent ALL cases.
Besides the pre-BCR itself, our data also highlight the importance of the downstream signaling molecules SYK, PI3K, FOXO1 and MYC. As indicated by the highly congruent GEP signature, the addiction of pre-BCR-dependent ALL to this signaling axis is most likely derived from its cell of origin, the pre-B lymphocyte (cytoplasmic Igμ + and surface IgM − ). It was previously established that mice deficient for key components of this pathway (including SYK, the catalytic PI3K subunits p110α and p110δ, and MYC) share a common phenotype with respect to B-cell development, characterized by a maturation arrest at the pre-B-cell stage and the absence of mature B cells. [57] [58] [59] [60] [61] Our data suggest that pre-B ALL cells remain dependent on this signaling axis, despite malignant transformation, and ensure its activation through signals directly from the pre-BCR and SYK.
In summary, we demonstrate that pre-BCR expression defines a subgroup of B-ALL that is exquisitely dependent on SYK and define regulatory downstream signaling and transcriptional events. Results from pharmacologic inhibition suggest that SYK is a valid therapeutic target in this subset of B-ALL patients.
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